Leap Therapeutics, Inc. (LPTX)
Automate Your Wheel Strategy on LPTX
With Tiblio's Option Bot, you can configure your own wheel strategy including LPTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LPTX
- Rev/Share 0.0
- Book/Share 0.505
- PB 0.7466
- Debt/Equity 0.0074
- CurrentRatio 2.4126
- ROIC -3.4179
- MktCap 15622692.0
- FreeCF/Share -1.436
- PFCF -0.2636
- PE -0.2249
- Debt/Assets 0.0044
- DivYield 0
- ROE -1.6215
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 4
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | LPTX | H.C. Wainwright | Buy | Neutral | -- | -- | Jan. 29, 2025 |
| Downgrade | LPTX | Robert W. Baird | Outperform | Neutral | $9 | $1.25 | Jan. 29, 2025 |
News
Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives
Published: June 23, 2025 by: PRNewsWire
Sentiment: Neutral
Updated data from DeFianCe study continue to demonstrate statistically significant improvements in PFS among the DKK1-high, VEGF-naïve and liver metastasis subgroups Board of Directors has initiated process to explore strategic alternatives to maximize shareholder value CAMBRIDGE, Mass. , June 23, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported updated results from Part B of the DeFianCe study (NCT05480306), a Phase 2 study of sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in combination with bevacizumab and chemotherapy (Sirexatamab Arm) compared to bevacizumab and chemotherapy (Control Arm) in patients with advanced microsatellite …
Read More
Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting
Published: April 25, 2025 by: PRNewsWire
Sentiment: Neutral
FL-501 fully restored body composition and reversed key indicators of cachexia in preclinical models Findings confirm GDF-15's role in cachexia and support advancing FL-501 into the clinic CAMBRIDGE, Mass. , April 25, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it will present preclinical data of FL-501 in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting taking place April 25-30 in Chicago, Illinois.
Read More
Leap Therapeutics (LPTX) Conference Call to discuss Updated Data from Part B of the DeFianCe Study Transcript
Published: March 31, 2025 by: Seeking Alpha
Sentiment: Neutral
Leap Therapeutics (NASDAQ:LPTX ) Conference Call to discuss Updated Data from Part B of the DeFianCe Study March 26, 2025 8:00 AM ET Company Participants Douglas Onsi - President and CEO Cyndi Sirard - Chief Medical Officer Jason Baum - Chief Scientific Officer Conference Call Participants Matthew Pipps - William Blair Swayampakula Ramakanth - H.C. Wainwright Operator Good morning.
Read More
Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer
Published: March 26, 2025 by: Benzinga
Sentiment: Positive
Leap Therapeutics, Inc. LPTX presented updated preliminary data on Wednesday from Part B of the DeFianCe Phase 2 trial of sirexatamab (DKN-01) in combination with bevacizumab and chemotherapy (Experimental Arm) compared to bevacizumab and chemotherapy (Control Arm).
Read More
Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study
Published: March 26, 2025 by: PRNewsWire
Sentiment: Neutral
Updated data confirms statistically significant 32% higher ORR and 3.5 month longer PFS in second-line CRC patients with high DKK1 levels treated with sirexatamab plus bevacizumab and chemotherapy Statistically significant 22% higher ORR and 2.6 month longer PFS in patients who had not had prior anti-VEGF therapy Leap to host a conference call to present clinical data today, March 26, 2025, at 8:00 a.m. ET CAMBRIDGE, Mass.
Read More
About Leap Therapeutics, Inc. (LPTX)
- IPO Date 2017-01-25
- Website https://www.leaptx.com
- Industry Biotechnology
- CEO Mr. Douglas E. Onsi J.D.
- Employees 52